Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction

被引：0

作者：

Mollee, Peter ^{[1
,2
]}

Boyle, Stephen ^{[1
]}

Wellard, Cameron ^{[3
]}

Moore, Elizabeth ^{[3
]}

Blacklock, Hilary ^{[4
]}

Harrison, Simon J. ^{[5
]}

Ho, P. Joy ^{[6
]}

Hocking, Jay ^{[7
]}

McQuilten, Zoe ^{[8
]}

Quach, Hang

Spearing, Ruth ^{[9
]}

Wood, Erica ^{[8
]}

Spencer, Andrew ^{[10
]}

机构：

[1] Princess Alexandra Hosp, Brisbane, Qld, Australia

[2] Univ Queensland, Brisbane, Qld, Australia

[3] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia

[4] Middlemore Hosp, Auckland, New Zealand

[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[6] Royal Prince Alfred Hosp, Camperdown, NSW, Australia

[7] Box Hill Hosp, Box Hill, Vic, Australia

[8] Monash Univ, SPHPM, Transfus Res Unit, Melbourne, Vic, Australia

[9] Christchurch Hosp, Christchurch, New Zealand

[10] Monash Univ, Alfred Hosp, Australian Ctr Blood Dis, Melbourne, Vic, Australia

来源：

关键词：

bortezomib; survival; Transplant-ineligible;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SP-062

引用

页码：E233 / E234

页数：2